The core and extended Adjuvant teams are comprised of experienced private equity investors, global public health leaders, disease-specific technical experts, and pharmaceutical industry veterans. Adjuvant’s deep ties to the global health community and its formal network of advisors gives the team a major information advantage over other healthcare investors.

To contact us, send an e-mail to

Core Investment Team

Glenn Rockman // Founding Partner

Jenny Yip // Partner

Kabeer Aziz // Principal

Charlie Petty // Principal

Michael Chang // Principal

Curt LaBelle // Venture Partner

Gerard Cunningham // Venture Partner


Before textAfter text

Prior to Adjuvant, Glenn launched and then co-managed the Global Health Investment Fund (GHIF), which was sponsored by the Bill & Melinda Gates Foundation and structured by J.P. Morgan’s Social Finance unit, where Glenn was an Executive Director. He is still active on a number of GHIF projects, including board seats on a number of innovative life sciences companies such as Univercells, Themis, and EuBiologics. Glenn also represented GHIF’s interests as a director at IanTech, which was acquired by Carl Zeiss Meditec in 2018.

Prior to his GHIF role, Glenn spent more than a decade as an investment banker at J.P. Morgan, where his practice focused on serving the financing needs of research institutions, charitable foundations, universities, and other non-profit organizations. He earned an AB in public policy from the Woodrow Wilson School of Public & International Affairs at Princeton University.

Before textAfter text

Ms. Yip has worked in finance for over 15 years, beginning as an investment banking analyst advising corporate clients in mergers & acquisitions, debt and equity financings in Goldman Sachs’ Hong Kong, New York, and San Francisco offices.  At Goldman, her clients included Google, Freescale Semiconductors, Matrix Technologies and Activision among others.  Ms. Yip was also selected by Goldman’s Investment Banking leadership to manage its San Francisco and Los Angeles offices and was responsible for recruiting and mentoring over 100 junior investment bankers, as well as business development and general business management of a group with ~$400 million of annual revenue.

Despite a promising career in corporate finance, Ms. Yip was always passionate about improving the health and lives of those living in lower and middle-income countries and has spent time working and living in Kenya and China.  In Kenya, Ms. Yip spent almost a year as a Volunteer Consultant for Technoserve, a non-profit business consultancy for small-holder farmers and small to medium businesses.  At Technoserve, Ms. Yip developed business models for small-holder maize farmers in rural Western Kenya, analyzed capital and financing gaps for East African entrepreneurs, and helped smaller foundations develop their charitable giving strategy.  In China, Ms. Yip spent time fundraising for a family-owned K-12 education business as it was looking for growth capital to expand its schools to China’s tier two cities.

In 2012, as the Gates Foundation was expanding its strategic investment efforts from a pilot program to a larger scale fund, BMGF recruited Ms. Yip to not only lead transactions across the Gates Foundation’s focus areas in Global Health, Agriculture, Nutrition and Education, but also be a part of a small team that pushed the envelope on how private foundations can use philanthropic capital and program-related investments to complete equity, debt, structured finance and guarantee investments in companies and investment funds to achieve charitable objectives.  By the end of Ms. Yip’s six-plus years as a senior leader at BMGF’s Strategic Investment Fund, the portfolio grew to $2 billion, with over 70 investments, 20 exits, and an investing staff of 12.  Ms. Yip personally led 12 transactions spanning the United States, Europe, China, India, and Africa, across a broad spectrum of asset classes and sectors. Ms. Yip’s work at BMGF frequently involved co-investing with traditional private equity and venture capital firms, charitable trusts, and other private donors.

Ms. Yip represented BMGF’s interests on numerous boards including Kymab (UK), Acrobatiq (US), Ustar Technologies (China), and Owl Ventures (USA).  Outside of the Gates Foundation, she also serves on the Advisory Committee for the Reproductive Health Investors’ Alliance (US).

Ms. Yip graduated magna cum laude from Harvard University with an AB in History of Science.

Before textAfter text

Kabeer helped found Adjuvant Capital after three years with the Global Health Investment Fund (GHIF). While at GHIF he was responsible for sourcing and analyzing new opportunities, including co-leading the fund’s investments in Univercells, Themis, Access Bio, and Atomo Diagnostics. He has supported projects across the entire GHIF portfolio and continues to be involved as a board observer to several active partnerships.

Prior to GHIF, Kabeer was an investment professional at Metalmark Capital, a private equity fund in New York, where he focused primarily on medical device investments. Kabeer also spent time at Greenhill & Co., a boutique investment bank, where he advised on M&A transactions in the biopharmaceutical and medical technology sectors. He graduated with honors from the Stern School of Business at New York University with a BS in Finance & Economics.

Before textAfter text

Charlie helped found Adjuvant Capital from the Global Health Investment Fund (GHIF), where he was responsible for sourcing and executing investments in medical device companies, including the fund’s investments in IanTech (acquired by Zeiss) and Alydia Health.

Prior to GHIF, Charlie was with Artemis Capital Partners, where he made private equity investments in industrial technology companies with a focus on the scientific instrumentation and advanced materials sectors. Previously, he lived and worked in Haiti at the country’s largest microfinance bank, Sevis Finansye Fonkoze, where he led financial and operational analysis efforts. Charlie remains actively involved in Haiti and serves on the boards of Sevis Finansye Fonkoze and Fonkoze USA.

He is a graduate of the Virginia Polytechnic Institute.

Before textAfter text

Michael joined the Adjuvant investment team from the Bill & Melinda Gates Foundation, where he worked with the foundation’s Global Health division and Strategic Investment Fund to structure investments into biotech companies, leading academic centers, and other non-profit organizations with the goal of stimulating technological innovation in global health. Michael has experience investing in the development of drugs, vaccines, diagnostics, and health data solutions across a wide range of high-burden and neglected disease areas.

Prior to the Gates Foundation, Michael spent several years covering the specialty pharmaceuticals sector as an equity research analyst at Piper Jaffray in New York. Michael started his career in the investment banking practice at Stifel, where he focused on M&A advisory. He earned a BA in International Relations from The Johns Hopkins University.

Before textAfter text

Mr. Cunningham, Founder and Principal at Innovations for Global Health (iGH), has 24 years of experience in the pharmaceutical and global health space. He has worked in the vaccine arena for the past 17 years, and led the new vaccine planning function at Merck.  He established iGH to support the assessment, acceleration, introduction and execution of global health innovations, guided by the belief that such innovations can significantly improve public health outcomes in low- and middle-income countries.  Mr. Cunningham leads iGH’s support for GHIF as a Senior Advisor to the Fund.

Mr. Cunningham spent more than three years working at the Bill & Melinda Gates Foundation (BMGF) where he supported the HIV, TB and Malaria program teams, and worked closely with a range of partners including multi-national corporations, emerging market manufacturers, WHO, UNICEF, Gavi and others to support delivery of new vaccines and the eradication of polio.

In addition, while at BMGF, he negotiated a number of partnerships to drive access to new vaccines. He was responsible for assessments of new technologies for IPV to support polio eradication as well as partner/supplier assessments including leadership of technical, financial and legal diligence efforts for multiple manufacturers.

Mr. Cunningham has an MA (Engineering) and an M. Eng. (Manuf. Engineering) degree from Cambridge University, in addition to an MBA (Marketing & International Business) from the University of Michigan.